

Rapid onset and long-acting relief of pain and inflammation.¹


The only **dual-action** injectable corticosteroid approved by the FDA for use in horses.



betamethasone sodium phosphate and betamethasone acetate injectable suspension



BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) is indicated for the control of pain and inflammation associated with osteoarthritis in horses.



The only dual-action betamethasone product proven safe and effective in horses.

- BetaVet[®] is a sterile aqueous suspension of betamethasone acetate in betamethasone sodium phosphate injection.
- Intra-articular (IA) corticosteroid injections, when used appropriately, are considered a cornerstone of therapy to reduce inflammation.
- Target animal safety (TAS) study² supported the FDA approval of BetaVet[®] when administered IA to horses in a maximum of 2 joints at a one-time dosing of 9 mg per joint.

For complete details of the BetaVet® Target Animal Safety Study visit betavetequine.com.

CONTRAINDICATIONS: BetaVet® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis. **Please see accompanying Full Prescribing Information or at** *www.betavetequine.com.* For additional Important Safety Information, please see next page.

proven A unique formula backed by science.


Controls pain and inflammation associated with equine osteoarthritis

O Unique equine formula with 2 active ingredients:

- Betamethasone sodium phosphate (3.15 mg²), a highly soluble betamethasone ester with a rapid onset of action¹
- Betamethasone acetate (2.85 mg²), a less soluble betamethasone ester with prolonged action
- Time to peak plasma (Tmax) concentrations achieved in as little as 4.5 to 8 hours* *Clinical significance of these results is unknown.

Pivotal field studies show over 75% efficacy.²

- BetaVet® clinical success rate of 75.73% (n=87) compared to Saline (Control) clinical success rate of 52.52% (n=61)
- Field efficacy study based on a negative control, randomized masked trial of 239 horses — BetaVet® n=114; Saline (Control) n=115
- Clinical success defined as improvement in one lameness grade according to the AAEP lameness scoring system, Day 5 after treatment



The most common adverse events included local swelling, mild increases in lameness, loose stool, increased heat in the treated joint, depression, anxiety and inappetance.

advantages The advantages of an FDA-Approved product.

As you choose and use products for your equine patients, your clients may want to know why you recommend one option over another.

When you choose BetaVet,[®] you can be sure you're administering an FDA-Approved product that's undergone rigorous clinical testing for both efficacy and safety in horses.

What sets BetaVet® apart?



*See triamcinolone reference #8.



Dosing and Administration

dosing

- Shake well immediately before use.
- Using strict aseptic technique, administer BetaVet 1.5 mL (9 mg total betamethasone) per joint by intra-articular injection.

BetaVet

NJECTABL

BetaVe

- May be administered concurrently in up to 2 joints per horse.
- Use immediately after opening; discard any remaining contents.

PRECAUTIONS: Corticosteroids, including BetaVet,[®] administered intra-articularly are systemically absorbed. Do not use in horses with acute infections.

INDICATION BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) is indicated for the control of pain and inflammation associated with osteoarthritis in horses. IMPORTANT SAFETY INFORMATION For Intra-articular [1.A.] use in Horses. CONTRAINDICATIONS BetaVet® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis. WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimes tee of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in congenital anomalies. Before use of orticosteroids in the presence of parturitions. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked. Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, should be approached with caution. Consider appropriate wash out times prior to administered either BetaVet® (n=119) or a saline control (n=120) at five percent (5%) and above were: acute joint effusion and/or local injection site swelling (within 2 days of injection), 15% BetaVet® and 13% saline control; increased lameness (within the first 5 days), 6.7% BetaVet® and 8.3% saline control; noose stool, 5.



From the manufacturer of Adequan[®] i.m. (polysulfated glycosaminoglycan), trusted by veterinarians for more than 30 years.

Want to learn more or place an order?

- Contact your American Regent, Inc., Sales Representative
- Call 1-800-458-0163
- Visit betavetequine.com

- 1. Trotter GW. Intra-articular corticosteroids. In: McIlwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia, PA; W.B. Saunders, 1996;237-256.
- 2. BetaVet Package Insert, Rev 1/19.
- 3. Knych HK, Stanley SD, Harrison LM and McKemie DS. Pharmacokinetics of Betamethasone in Plasma, Urine and Synovial Fluid Following Intra-Articular Administration to Exercised Thoroughbred Horses, 2017.
- Foland JW, McIlwraith CW, Trotter GW, Powers BE, and Lamar CH. Effect of Betamethasone and Exercise on Equine Carpal Joints With Osteochondral Fragments, Veterinary Surgery, 23:639-376, 1994.
- Frisbie D. New Research and Regulatory Issue Associated with Corticosteroids, Proceedings of the Annual Convention of the AAEP 2000.
- 6. ARCI Controlled Therapeutic Medication Schedule for Horses; V4.0
- (Rev. April 20, 2017)
- 7. RMTC Approved Controlled Therapeutic Medications
- 8. FEI List of Detection Times, Fédération Equestre Internationale (FEI), 13 Jul 2018.

All trademarks are the property of American Regent, Inc. © 2021 American Regent, Inc. PP-BV-US-0045 11/2021

Please see accompanying Full Prescribing Information or at www.betavetequine.com.





BETAVET®

(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension)

BETAVET®

(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension)

6 mg betamethasone per mL For Intra-Articular (I.A.) Use in Horses


CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION

BETAVET® is a sterile aqueous suspension of betamethasone acetate in betamethasone sodium phosphate injection. The combined betamethasone content of the suspension is 6 mg/mL where each mL contains 3.15 mg betamethasone (as betamethasone sodium phosphate); 2.85 mg betamethasone (as betamethasone acetate); 7.1 mg dibasic sodium phosphate; 3.4 mg monobasic sodium phosphate; 0.1 mg edetate disodium; and 0.2 mg benzalkonium chloride, as a preservative in water for injection. The pH is adjusted to between 6.8 and 7.2.

The formula for betamethasone sodium phosphate is C₂₂H₃₂FNa₂O₂P and it has a molecular weight of 516.41. be administered until joint sepsis has been definitively ruled Chemically, it is 9-Fluoro-11β, 17,21-trihydroxy-16β- out. methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate).

The formula for betamethasone acetate is $G_{a}H_{3}FO_{a}$ and it has a molecular weight of 434.50. Chemically, it is 9-Fluoro-116,17,21-trihydroxy-166-methylpregna-1,4-diene-3,20dione 21-acetate

The chemical structures for betamethasone sodium phosphate and betamethasone acetate are as follows:



Betamethasone sodium phosphate is a white to practically white, odorless powder, and is hygroscopic. It is freely soluble in water and in methanol, but is practically insoluble in acetone and in chloroform.

Betamethasone acetate is a white to creamy white, odorless powder that sinters and resolidifies at about 165°C, and remelts at about 200°C-220°C with decomposition. It is practically insoluble in water, but freely soluble in acetone, and is soluble in alcohol and in chloroform.

INDICATION

BETAVET is indicated for the control of pain and inflammation associated with osteoarthritis in horses

DOSAGE AND ADMINISTRATION

Shake well immediately before use.

Using strict aseptic technique, administer 1.5 mL BETAVET (9 mg total betamethasone) per joint by intra-articular injection. BETAVET may be administered concurrently in up

to 2 joints per horse

Use immediately after opening, then discard any remaining contents.

CONTRAINDICATIONS

BETAVET is contraindicated in horses with hypersensitivity

Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.

WARNINGS

Do not use in horses intended for human consumption.

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia and anasarca. Therefore, before use of corticosteroids in pregnant

CLINICAL PHARMACOLOGY

Betamethasone is a potent olucocorticoid steroid with anti-inflammatory and immunosuppressive properties Depending upon their physico-chemical properties drugs administered intra-articularly may enter the general circulation because the synovial joint cavity is in direct equilibrium with the surrounding blood supply. After the intra-articular administration of 9 mg BETAVET in horses, there were quantifiable concentrations of betamethasone (above 1.0 ng/mL) in the plasma. Maximum plasma concentrations (C_{max}) and time to C_{max} (T_{max}) values ranged from 2.70 to 3.88 ng/mL and 4.5 to 8 hours, respectively. The effective plasma terminal elimination half-life ranged from 4 to 8 hours. The non-compartmental area-underthe curve to the limit of quantification (AUC_{LOD}) ranged from 29.24 to 42.96 hr*ng/mL. In contrast, most of the betamethasone disodium phosphate concentrations and all of the betamethasone acetate concentrations were below the limit of quantification in plasma.

EFFECTIVENESS

animals, the possible benefits to the pregnant animal should

be weighed against potential hazards to its developing

Human Warnings: Not for use in humans. For use in animals only. Keep this and all medications out of the reach

of children. Consult a physician in the case of accidental

Corticosteroids, including BETAVET, administered intra-

articularly are systemically absorbed. Do not use in horses

Acute moderate to severe exacerbation of pain, further

loss of joint motion, fever, or malaise within several days

following intra-articular injection may indicate a septic

corticosteroids, signs of infection in the treated joint may be

masked. Appropriate examination of joint fluid is necessary

to exclude a septic process. If a bacterial infection is present

appropriate antibacterial therapy should be instituted

immediately. Additional doses of corticosteroids should not

Due to the potential for exacerbation of clinical signs of

laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a

Use with caution in horses with chronic nephritis, equine

pituitary pars intermedia dysfunction (PPID), and congestive

Concurrent use of other anti-inflammatory drugs, such as

NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure.

concomitant use of NSAIDs and corticosteroids may

increase the risk of gastrointestinal, renal, and other toxicity

Consider appropriate wash out times prior to administering

Adverse reactions reported during a field study of 239

horses of various breeds which had been administered

either BETAVET (n=119) or a saline control (n=120) are

summarized in Table 1. One BETAVET treated horse was

removed from the study for onset of acute non-weight

bearing lameness on Day 4. Treatment for presumed

joint sepsis was instituted immediately, but the horse

was eventually euthanized several weeks later due to

intravenous catheter placement. One BETAVET treated horse

developed bilateral forelimb lameness on Day 8, with snow

packed in the shoes and poor hoof conformation noted by

the investigator. The horse was diagnosed with laminitis

Radiographs showed no abnormalities, and the horse was

Number (%) of BETAVET

18 (15%)

8 (6.7%)

7 (5.9%)

3 (2.5%)

7 (5.9%)

5 (4.2%)

3 (2.5%)

4 (3.4%)

2 (1.7%)

1 (0.8%)

1 (0.8%)

1 (0.8%)

treated

orses

Number (%) of saline

16 (13%)

10 (8.3%)

10 (8.3%)

6 (5%)

2 (1.6%)

3 (2.5%)

4 (3.3%)

3 (2.5%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

treated

horses

sound shortly after shoeing changes were implemented.

thromboembolic event associated with prolonged

additional NSAIDs or corticosteroids.

Because of the anti-inflammatory action of

embryo or fetus

human exposure.

PRECAUTIONS

process.

with acute infections.

higher risk for laminitis.

ADVERSE REACTIONS

Table 1. Adverse Reactions

Adverse Reaction

Acute joint effusion

of injection)

oose stool

Depression

Inappetance

Dry stool

Laminitis

Agitation/anxiety

Delayed swelling of

Excessive sweating

Acute non-weight

bearing lameness

treated joint (5 or more days after injection)

and/or local injection site

swelling (within 2 days

Increased lameness (within the first 5 days)

Increased heat in joint

heart failure.

A negative control, randomized, masked field study provided data to evaluate the effectiveness of BETAVET administered at 1.5 mL (9 mg betamethasone) once intra-articularly for the control of pain and inflammation associated with osteoarthritis in horses. A total of 119 horses received BETAVET and 120 horses received saline. 229 horses were included in the final effectiveness analysis. Clinical success was defined as improvement in one lameness grade according to the AAEP lameness scoring system on Day 5 following treatment. Table 2 summarizes the clinical success and failure in each treatment group on Day 5. The success rate for horses in the BETAVET group was statistically significantly different (p=0.0061) than that in the saline group, with success rates of 75.73% and 52.52%, respectively (back-transformed from the logistic rearession).

Table 2. Clinical Effectiveness Results

	BETAVET (n=114)	Saline (n=115)
Number of Successes	87	61
Number of Failures	27	.54

A 3-week target animal safety (TAS) study was conducted to evaluate the safety of BETAVET in mature, healthy horses. The study was designed with 4 treatment groups of 8 horses in each group. Treatment groups included a control (isotonic saline at a volume equivalent to the 4x group); 1X (0.0225 mg betamethasone per pound bodyweight; BETAVET); 2X (0.045 mg betamethasone per pound bodyweight; BETAVET) and 4X (0.09 mg betamethasone per pound bodyweight; BETAVET). Treatments were administered by intra-articular injection into the left middle carpal joint once every 5-days for 3 treatments

Injection site reactions were the most common observations in all treatment groups. Injection site reactions were observed within 1 hour of dosing and included swelling at the injection site, lameness/stiffness of the left front limb, and flexing the left front knee at rest (see table 3).

Table 3. Incidence of Injection Site Reactions

Group	Total Swelling Observations	Excessive/ obvious swelling	Pain at injection site	Knee flexed at rest	Lame or stiff
0x	14	4	0	0	0
1x	6	1	0	0	0
2x	11	2	0	0	0
4x	18	10	3	3	2
of injec hird in 10 > da number	and severity of tion site react ajection (numb ay 5 > day 0). and severity ependent. The	ions increase per of abnor In the BETA	ed after th malities VET treat	ne seco noted o ed grou	nd an

in the BETAVET treated groups as compared to the control group. Trends toward a decrease in lymphocytes and eosinophils, and an increase in monocytes were identified in the BETAVET treated groups after the initial dose of BETAVET. Individual animal values for white blood cells generally remained within the reference range. BETAVET treated horses also had a trend toward increased blood glucose after the initial dose. Some individual animals showed mild increases in blood glucose above the reference range.

STORAGE CONDITIONS

Store at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from light. Use carton to protect contents from light until used

HOW SUPPLIED

BETAVET, containing 30 mg betamethasone/5 mL (6 mg betamethasone/mL) in 5 mL vials.

NDC 10797-720-01 5 mL Vials Packaged in boxes of 1 SHAKE WELL BEFORE USING

NADA 141-418, Approved by FDA AMERICAN REGENT, INC. ANIMAL HEALTH Shirley, NY 11967

Rev. 01/2019 BQ1053-01

(631) 924-4000

(800) 458-0163